Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12805714 | 1.00 | TGFBR1 (0.41) | TGFBR1MEN1GAAKMT2AMME | |
| SCHEMBL4096308 | 0.86 | CTSK (0.42) | MEN1GAAKMT2ACYP2D6PTPRC | |
| SCHEMBL1162877 | 0.86 | CTSK (0.42) | MEN1GAAKMT2ACYP2D6PTPRC | |
| SCHEMBL4971083 | 0.86 | CTSK (0.42) | MEN1GAAKMT2ACYP2D6PTPRC | |
| SCHEMBL8751934 | 0.84 | CYP2D6 (0.36) | MEN1GAAKMT2ACYP2D6PTPRC | |
| SCHEMBL21877890 | 0.84 | GRN (0.38) | TGFBR1MEN1GAAKMT2ACYP2D6 | |
| SCHEMBL18248134 | 0.84 | CTSK (0.46) | MEN1GAAKMT2ACYP2D6PTPRC | |
| SCHEMBL21877891 | 0.84 | GRN (0.38) | TGFBR1MEN1GAAKMT2ACYP2D6 | |
| SCHEMBL2586168 | 0.84 | MEN1 (0.36) | MEN1GAAKMT2ACYP2D6PTPRC | |
| SCHEMBL1162906 | 0.84 | MEN1 (0.36) | MEN1GAAKMT2ACYP2D6PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464321-B1 | PROTEASOME INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-11345724-B2 | Proteasome inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20200325171-A1 | PROTEASOME INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-10-15 | — | — | US | disclosed |
| EP-3464321-A1 | PROTEASOME INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017211818-A1 | PROTEASOME INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-12-14 | — | — | WO | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| EP-2513066-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325171-A1 | PROTEASOME INHIBITORS | PSMB1, PSMB2, PSMB5 | TGFBR1 586/4885MEN1 2770/4885GAA 869/4885 |
| US-11345724-B2 | Proteasome inhibitors | PSMB1, PSMB2, PSMB5 | TGFBR1 583/4885MEN1 3000/4885GAA 774/4885 |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, S1PR3, SPHK2 | TGFBR1 2608/4885MEN1 380/4885GAA 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.